HF Advisory Group LLC Acquires 3,996 Shares of Becton, Dickinson and Company $BDX

HF Advisory Group LLC grew its holdings in shares of Becton, Dickinson and Company (NYSE:BDX) by 70.5% in the 1st quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The institutional investor owned 9,666 shares of the medical instruments supplier’s stock after acquiring an additional 3,996 shares during the quarter. HF Advisory Group LLC’s holdings in Becton, Dickinson and Company were worth $1,520,000 at the end of the most recent quarter.

A number of other institutional investors and hedge funds have also recently made changes to their positions in BDX. Crux Wealth Advisors grew its holdings in shares of Becton, Dickinson and Company by 0.8% during the 4th quarter. Crux Wealth Advisors now owns 6,297 shares of the medical instruments supplier’s stock valued at $1,222,000 after purchasing an additional 49 shares during the last quarter. Larson Financial Group LLC lifted its stake in Becton, Dickinson and Company by 1.7% in the 4th quarter. Larson Financial Group LLC now owns 3,230 shares of the medical instruments supplier’s stock valued at $627,000 after purchasing an additional 53 shares during the last quarter. Camelot Portfolios LLC boosted its position in Becton, Dickinson and Company by 1.5% in the fourth quarter. Camelot Portfolios LLC now owns 3,545 shares of the medical instruments supplier’s stock valued at $688,000 after buying an additional 54 shares in the last quarter. McElhenny Sheffield Capital Management LLC grew its stake in shares of Becton, Dickinson and Company by 3.6% during the fourth quarter. McElhenny Sheffield Capital Management LLC now owns 1,590 shares of the medical instruments supplier’s stock worth $309,000 after buying an additional 55 shares during the last quarter. Finally, Atlantic Union Bankshares Corp grew its stake in shares of Becton, Dickinson and Company by 0.9% during the fourth quarter. Atlantic Union Bankshares Corp now owns 6,108 shares of the medical instruments supplier’s stock worth $1,185,000 after buying an additional 57 shares during the last quarter. Institutional investors own 86.97% of the company’s stock.

Insider Activity

In related news, EVP Michael David Garrison sold 1,100 shares of the business’s stock in a transaction on Wednesday, June 24th. The shares were sold at an average price of $145.66, for a total value of $160,226.00. Following the transaction, the executive vice president owned 13,172 shares in the company, valued at $1,918,633.52. The trade was a 7.71% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, CEO Thomas E. Polen, Jr. sold 2,764 shares of the business’s stock in a transaction dated Monday, June 1st. The shares were sold at an average price of $146.35, for a total value of $404,511.40. Following the completion of the transaction, the chief executive officer directly owned 110,163 shares in the company, valued at $16,122,355.05. This represents a 2.45% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. In the last three months, insiders sold 5,188 shares of company stock valued at $765,120. Insiders own 0.40% of the company’s stock.

Analyst Upgrades and Downgrades

A number of research analysts have recently commented on the company. TD Cowen dropped their price target on Becton, Dickinson and Company from $189.00 to $163.00 and set a “hold” rating for the company in a research note on Monday, May 4th. Stifel Nicolaus reduced their price objective on Becton, Dickinson and Company from $215.00 to $175.00 in a research report on Thursday, May 7th. Bank of America lowered their target price on Becton, Dickinson and Company from $177.00 to $170.00 in a report on Friday, June 12th. Wells Fargo & Company increased their target price on Becton, Dickinson and Company from $157.00 to $161.00 and gave the company an “equal weight” rating in a research report on Friday, May 8th. Finally, Zacks Research raised Becton, Dickinson and Company from a “strong sell” rating to a “hold” rating in a research note on Friday, April 10th. Seven investment analysts have rated the stock with a Buy rating, eight have given a Hold rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat.com, the stock presently has an average rating of “Hold” and a consensus target price of $181.00.

Becton, Dickinson and Company Price Performance

BDX stock opened at $156.06 on Friday. The company has a market capitalization of $43.00 billion, a P/E ratio of 39.51, a PEG ratio of 10.72 and a beta of 0.22. The company has a fifty day moving average price of $148.17 and a 200-day moving average price of $170.75. The company has a debt-to-equity ratio of 0.62, a quick ratio of 0.55 and a current ratio of 0.94. Becton, Dickinson and Company has a 52-week low of $127.59 and a 52-week high of $187.35.

Becton, Dickinson and Company (NYSE:BDX) last issued its quarterly earnings data on Thursday, May 7th. The medical instruments supplier reported $2.90 earnings per share for the quarter, topping the consensus estimate of $2.77 by $0.13. The company had revenue of $4.71 billion for the quarter, compared to analysts’ expectations of $4.67 billion. Becton, Dickinson and Company had a net margin of 5.33% and a return on equity of 15.37%. Becton, Dickinson and Company’s revenue for the quarter was up 5.2% on a year-over-year basis. During the same quarter in the previous year, the firm posted $3.35 earnings per share. Becton, Dickinson and Company has set its FY 2026 guidance at 12.520-12.720 EPS. As a group, equities analysts expect that Becton, Dickinson and Company will post 12.61 EPS for the current year.

Becton, Dickinson and Company Announces Dividend

The business also recently declared a quarterly dividend, which will be paid on Tuesday, June 30th. Shareholders of record on Tuesday, June 9th will be given a $1.05 dividend. This represents a $4.20 dividend on an annualized basis and a dividend yield of 2.7%. The ex-dividend date is Tuesday, June 9th. Becton, Dickinson and Company’s payout ratio is 106.33%.

Becton, Dickinson and Company Company Profile

Becton, Dickinson and Company (BDX) is a global medical technology company that develops, manufactures and sells a broad range of medical devices, instrument systems and reagents. BD’s products are used by healthcare institutions, clinical laboratories, life science researchers and the pharmaceutical industry to enable safe, effective delivery of care, specimen collection and diagnostic testing. The company’s operations span multiple business areas focused on medical devices, life sciences research tools and interventional technologies.

BD’s product portfolio includes single-use medical devices such as syringes, needles, needlesafety and injection systems, infusion therapy and medication management solutions, as well as vascular access, urology and oncology devices acquired through its interventional business.